travere pharma - MARKETS
Fierce Pharma: Despite uncertainties, Travere’s Filspari emerges as first FDA-approved FSGS treatment Travere Therapeutics received approval from the Food and Drug Administration for a treatment for a rare kidney disorder. The biopharmaceutical company said Monday the approval is for its Filspari drug ... Stocktwits on MSN: Travere Therapeutics, Ligand in focus as FDA set to rule on Filspari next week – first FSGS drug at stake The FDA had extended the review of its supplemental New Drug Application for Filspari in January 2026.
Understanding the Context
・Citi kept a $48 price target for Travere, adding that it expects the FDA to approve the drug. Travere Therapeutics, Ligand in focus as FDA set to rule on Filspari next week – first FSGS drug at stake The Joplin Globe: Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has approved FILSPARI ® (sparsentan) to reduce proteinuria in adult and pediatric patients ... Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS